Heraeus Medical, Inc.
Heraeus Medical, Inc., a prominent player in the medical technology industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1851, the company has established itself as a leader in the development of innovative biomaterials and medical devices, particularly in orthopaedics and trauma care. Heraeus Medical is renowned for its core products, including bone cements and surgical solutions, which are distinguished by their superior quality and performance. The company’s commitment to research and development has led to significant advancements in patient care, solidifying its market position as a trusted provider in the healthcare sector. With a rich history and a focus on enhancing surgical outcomes, Heraeus Medical continues to set benchmarks in the medical field.
DitchCarbon Score
How does Heraeus Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Electrical Machinery Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Heraeus Medical, Inc.'s score of 28 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Heraeus Medical, Inc.'s reported carbon emissions
In 2023, Heraeus Medical, Inc. reported total carbon emissions of approximately 1,707,000 kg CO2e, comprising 645,000 kg CO2e from Scope 1 and 1,063,000 kg CO2e from Scope 2 emissions. This marks a notable reduction from 2021, where total emissions were about 15,000,000 kg CO2e, including 814,000 kg CO2e from Scope 1, 1,014,000 kg CO2e from Scope 2, and 14,798,310 kg CO2e from Scope 3 emissions. In 2022, the company maintained similar levels of Scope 1 and Scope 2 emissions as in 2021, with Scope 1 at 814,000 kg CO2e and Scope 2 at 1,063,000 kg CO2e, while Scope 3 emissions were significantly reduced to about 54.1 kg CO2e. Despite these figures, Heraeus Medical has not publicly disclosed specific reduction targets or initiatives aimed at further decreasing their carbon footprint. The absence of defined climate pledges or SBTi (Science Based Targets initiative) commitments suggests that while the company is actively monitoring its emissions, it may not yet have formalised a comprehensive strategy for long-term climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 814,000 | 000,000 | 000,000 |
| Scope 2 | 1,014,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 14,798,310 | 00.0 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Heraeus Medical, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
